Oncolytics receives 17th patent for methods to identify susceptibility of cells to reovirus

By E. Janene Geiss

Philadelphia, May 31 - Oncolytics Biotech Inc. said Wednesday that it has been granted U.S. Patent No. 7,052,832 entitled "Methods for the Treatment of Cellular Proliferative Disorders."

The claims describe methods of identifying the susceptibility of cells to reovirus infection, which is important in the future development of Reolysin, its proprietary formulation of human reovirus, according to a company news release.

"This patent provides coverage for methods of identifying patients that should have a high likelihood of response to reovirus treatment, by measuring Ras-MAP signaling through biopsies or other biological samples collected from those patients," Matt Coffey, chief scientific officer of Oncolytics, said in the release.

Oncolytics is a Calgary, Alta., biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.